CURRICULUM VITAE
September 26, 2014.
Name: Luis Z. Ostrosky, M.D., FACP, FIDSA, FSHEA
CONTACT INFORMATION: Division of Infectious Diseases 6431 Fannin, MSB 2.112 Houston, TX 77030 E-mail: [email protected] Office: (713) 500-6734 Fax: (713) 500-5495 LANGUAGES
Speaks Reads Writes Translates
Spanish 100% 100% 100% 100%
English 100% 100% 100% 100%
PROFESSIONAL EDUCATION
• Medical Doctor, Facultad de Medicina, Universidad Nacional Autonoma de México, México, 1989-1995.
• Internal Medicine Residency, Instituto Nacional de la Nutrición Salvador Zubirán/ Universidad Nacional Autonoma de México, México, 1995-1999.
• Infectious Diseases Fellowship, University of Texas- Houston Medical School and M.D. Anderson Cancer Center, Houston, Texas, USA, 1999-2002.
ADVANCED TRAINING
• SHEA/CDC Training Course in Hospital Epidemiology, 2001.
___________________________________________________________________________
CERTIFICATION & LICENSURE
• License to practice medicine in Mexico, 1995.
• ECFMG certificate obtained in 1995, valid indefinitely since 1999. • Mexican Board of Internal Medicine, February 1999.
• Medical License, Texas State Board of Medical Examiners, 2002. POSITIONS HELD
• Assistant Professor, Surgical Therapeutics I, Department of Surgery, Facultad de Medicina de la Universidad Nacional Autonoma de Mexico, 1991.
• Clinical Instructor, Instituto Nacional de la Nutricion Salvador Zubiran and Facultad de Medicina- Universidad Nacional Autonoma de Mexico, 1995-1998.
• Assistant Professor, Pharmacology, Facultad Mexicana de Medicina, Universidad La Salle, Mexico, January-June, 1999.
• Professor, Hospital Epidemiology Diploma, Division de Epidemiologia Hospitalaria, Instituto Nacional de la Nutrición Salvador Zubiran, May-June, 1999.
• Chief Resident, Internal Medicine, Instituto Nacional de la Nutrición Salvador Zubirán, México, December 1998-February1999.
• Researcher/physician, Division of Hospital Epidemiology, Instituto Nacional de la Nutrición Salvador Zubirán, México, March-June 1999.
• Instructor of Medicine, University of Texas- Houston Medical School, August 2002- December 2002.
• Assistant Professor of Medicine, University of Texas- Houston Medical School, January 2003- August 2006.
• Associate Professor of Medicine, University of Texas- Houston Medical School, September 2006- August 2011.
• Professor of Medicine, University of Texas- Houston Medical School, since September 2011. Tenure awarded September 2008.
• Assistant Professor of Epidemiology, University of Texas School of Public Health, since November 2003- August 2006.
• Associate Professor of Epidemiology, University of Texas School of Public Health, since September 2006. Tenure awarded September 2008.
• Professor of Epidemiology, University of Texas School of Public Health, since September 2011. Tenure awarded September 2008.
• Associate Program Director, Infectious Diseases Fellowship Program, University of Texas- Houston Medical School, since August 2002.
• Assistant Hospital Epidemiologist, Memorial Hermann Hospital, October-December 2002.
• Medical Director for Hospital Epidemiology, Memorial Hermann Hospital, since January 2003.
• Medical Director for Epidemiology, Memorial Hermann Healthcare System, December 2005- January 2008.
• Quality Officer, Division of Infectious Diseases, University of Texas- Houston Medical School, since September 2011.
• Associate Medical Director for Epidemiology, UT Physicians, since August 2013.
• New Curriculum Module Co-Director, Hematology and Pathogen Defense, University of Texas- Houston Medical School, since September 2014.
COMMITTEE AND BOARD MEMBERSHIP
• Texas Department of Health Judicious Use of Antibiotics Committee, since 2002. • Infection Control Committee, Hermann Hospital, since 2002. Chair since 2010. • Performance Improvement Review Committee, Hermann Hospital, since 2003. • Texas Department of Health Advisor on Smallpox Vaccination, since 2003.
• Biological Safety Committee, University of Texas Health Science Center, since 2003. • NIH/NIAD Bacteriology and Mycology Study Group, 2003-2007.
• University of Texas System Institutional Biosafety Committee, since 2004.
• New Investigator Development Program Advisory Committee, University of Texas Health Science Center, since 2004.
• Continuing Medical Education Committee, Memorial Hermann Healthcare System, 2005-2009.
• Committee for the Protection of Human Subjects, University of Texas Health Science Center, 2005-2009.
• Evidence-based practice committee, Memorial Hermann Hospital, 2005-2009.
• Search committee for the director of the contracts office (office of sponsored projects), 2005.
• Texas State Department of Health Services Advisory Panel on Healthcare-acquired infections, 2005-2006.
• Chair, University of Texas Health Science Center at Houston task force of on influenza preparedness, since 2005.
• Texas Medical Center pandemic influenza preparedness committee, 2006-2007.
• Chair, Memorial Hermann Healthcare System Infectious Diseases Subcommittee, 2006-2008.
• Infectious Diseases Society of America Standards and Practice Committee, 2006-2012.
• Infectious Diseases Society of America Invasive Candidiasis Guideline Writing Group, since 2006.
• Clinical Laboratory Standards Institute Committee on Antifungal Susceptibility Testing, since 2007.
• Candida work group, USPHS/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections. Starting 2007.
• Mycoses Study Group, starting 2007.
• Mycoses Study Group education committee, starting 2007.
• Faculty, Memorial Hermann/UT Medical School at Houston Physician Quality and Safety Academy, 2008.
• UT System collaborative on infection control, 2009-2012.
• Consultant, Food and Drug Administration Obstetrics and Gynecology Devices Panel, 2010-2013.
• Clinical consultant, Centers for Disease Control and Prevention, 2012 fungal meningitis outbreak, October 2012.
• Committee member, Awards Committee, Society of Healthcare Epidemiology of America, since 2013.
• Member, Anti-Infective Drug Advisory Committee, Food and Drug Administration, 2013-ongoing.
• Councilor (South-West), Medical Mycology Society of the Americas, since 2013.
• Chairman, Infectious Diseases Society of America Standards and Practice Committee, October 2013-Ongoing.
• Advisory board member, International Pediatric Fungal Network, since 2014. • Member, Research Conflict of Interest Committee, UTHealth, since 2014. • Member, Mycoses Study Group Steering Committee, since 2014.
HONORS, AWARDS, DISTINCTIONS, SCHOLARSHIPS AND GRANTS
• Maimonides Scholarship, Facultad de Medicina, Universidad Nacional Autonoma de México, 1991 and 1992.
• High Achievement diploma for maintaining an average of in medical school, awarded in 1990, 1991, 1992, 1993 and 1994.
• Selected by Facultad de Medicina, Universidad Nacional Autonoma de Mexico for an academic exchange program with the University of New Mexico, 1992.
___________________________________________________________________________
• Honors during pre-graduate internship at Instituto Nacional de la Nutrición Salvador Zubiran.
• Graduated from medical school with honors in January 1995, overall average , class standing
• Name entered in the gallery of outstanding students, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, December 1995.
• Gabino Barreda Medal awarded by Universidad Nacional Autonoma de Mexico to the best student of each of its graduate schools, 1996.
• Second prize winner in the Epidemiology Category, Xth Annual Research Award, Glaxo-Wellcome Foundation, Mexico 1999.
• George M. McCracken Fellow, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000.
• George M. McCracken Fellow, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, December 2001.
• Faculty Honors in Research, University of Texas Health Science Center at Houston, September 25th, 2003.
• Thomas J. Walsh Clinical Mycology Award, Focus on Fungal Infections 14, March 24-26, 2004.
• Faculty Honors in Research, University of Texas Health Science Center at Houston, October 6th, 2004.
• Faculty Honors in Research, University of Texas Health Science Center at Houston, October 18th, 2006.
• UT System Clinical Safety and Effectiveness award- Third place, 2009.
• 2012 Annual Infection Specialty Award, Society of Critical Care Medicine, 2012.
• 2011-2012 Dean’s Teaching Excellence Award, UT Health Medical School at Houston, 2012.
___________________________________________________________________________
RESEARCH EXPERIENCE
• Visiting student, Laboratory of Developmental Biology/Center for Craniofacial Molecular Biology, University of Southern California, USA, July and August- 1984 through 1989. Research Subject: Odontogenesis and dental protein biochemistry. • Visiting student, Laboratory of Immunochemistry, Weizmann Institute of Science,
Israel, March and April- 1988. Research Subject: Schistosoma mansoni antigen purification.
• Member, laboratory, Department of immunology of the Instituto de Investigaciones Biomédicas/Facultad de Medicina, Universidad Nacional Autonoma de Mexico 1987-1990. Research subjects: physiology, immunology, molecular biology and public health issues of cysticercosis/taeniasis.
• Social service in research, performed at the Neuroimmunology laboratory and Infectious Diseases Department of the Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez", under the tutoring of 1994. Research subjects: Cytokine/cellular immune response to neurocysticercosis, cellular immune response/immunemodulation of AIDS and its central nervous system opportunistic infections, clinical research in infectious diseases of the central nervous system, animal models and drug research for cryptococcosis and cryptococcal strain epidemiology.
• Researcher, Division of Hospital Epidemiology, Instituto Nacional de la Nutrición Salvador Zubirán, México. Tutoring by M.Sc., 1999. Research subjects: Hospital epidemiology and quality control, employee health, hospital outbreak investigations, AIDS, general infectious diseases.
• Director, Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine and Center for the Study of Emerging and Re-emerging Pathogens, University of Texas- Houston Medical School, Houston, Texas, USA. Mentoring by 1999-2002. Research subjects: Antifungal susceptibility testing, medical mycology, epidemiology, diagnostics, mycology clinical trials, and antifungal pharmacology.
PUBLICATIONS ___________________________________________________________________________ (b) (6) (b) (6) (b) (6) (b) (6)
Abstracts
1. Ostrosky-Zeichner L, Soto-Hernandez JL, Angeles-Morales V, Lopez-Martinez R, Castanon-Olivares LR, Sotelo J. Crytococcus neoformans var. gattii: Un patogeno relevante para pacientes con criptococosis meningea en Mexico, abstr. 82. In Program and abstracts of XIX Congreso Anual de la Asociacion Mexicana de Infectologia, Monterrey, Nuevo Leon, Mexico, 1994.
2. Ostrosky-Zeichner L, Soto-Hernandez JL, Tavera-Guittins GA, Gomez-Avina A, Del Valle R, Sotelo J. Neurocisticercosis en pacientes con SIDA, abstr. 84. In Program and abstracts of XIX Congreso Anual de la Asociacion Mexicana de Infectologia, Monterrey, Nuevo Leon, Mexico, 1994.
3. Ostrosky-Zeichner L, Soto-Hernadez JL, Angeles V, Teixeira F, Nava C, Rios C, Solis F, Sotelo J. Un modelo murino experimental de neuroinfeccion avanzada por Cryptococcus neoformans var. gattii: Evidencia de mecanismos fisiopatogenicos inmunologicos/neuroexcitatorios y nuevas estrategias terapeuticas, abstr. 83. In Program and abstracts of XIX Congreso Anual de la Asociacion Mexicana de Infectologia, Monterrey, Nuevo Leon, Mexico, 1994.
4. Ostrosky-Zeichner L, Baez R, Rangel S, Ponce de Leon S. Epidemiologia de los brotes nosocomiales: Experiencia de catorce anos en un centro hospitalario de tercer nivel, abstr. D001. In Program and abstracts of XXIV Congreso Anual de la Asociacion Mexicana de Infectologia y Microbiologia Clinica, Morelia, Michoacan, Mexico, 1999.
5. Ostrosky-Zeichner L, Vazquez A, Rangel-Frausto S, Garcia E, Ibarra MJ, Ponce de Leon S. Resultados de un programa de vigilancia de tuberculosis en trabajadores de un centro hospitalario de tercer nivel: 1992-1998, abstr. D009. In Program and abstracts of XXIV Congreso Anual de la Asociacion Mexicana de Infectologia y Microbiologia Clinica, Morelia, Michoacan, Mexico, 1999.
6. Huertas M, Ostrosky-Zeichner L, Sifuentes Osornio J, Bobadilla de Valle M, Ponce de Leon A, Bobadilla J, Rangel-Frausto S, Ponce de Leon S. Brote de colangitis/bacteremia por Pseudomonas aeruginosa relacionado a la relajacion de procedimientos de desinfeccion y esterilizacion en una unidad de endoscopia, abstr. D013. In Program and abstracts of XXIV Congreso Anual de la Asociacion Mexicana de Infectologia y Microbiologia Clinica, Morelia, Michoacan, Mexico, 1999.
7. Tlatempa-Leyva L, Huertas-Jimenez M, Ostrosky-Zeichner L, Rangel-Frausto MS, Ponce de Leon Rosales S, Ibarra-Blancas J, Romero-Oliveros C, Baez-Martinez R. Costo-beneficio de un equipo pre-empacado IV start pak, comparado con equipos tradicionales para instalcion y curacion de cateteres cortos, abstr. D026. In Program
and abstracts of XXIV Congreso Anual de la Asociacion Mexicana de Infectologia y Microbiologia Clinica, Morelia, Michoacan, Mexico,1999.
8. Ostrosky-Zeichner L, Baez-Martinez R, Rangel-Frausto MS, Ponce de Leon-Rosales S. Epidemiology of nosocomial outbreaks: 14-years’ experience at a tertiary care center, abstr. P-M1-35. In program and abstracts of 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia, USA, 1999.
9. Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In Vitro Antifungal Susceptibilities of Trichosporon Species, abstr. 935. In Program and abstracts of 40th Interscience Conference on Antimicrobial Agents and
Chemotherapy, Toronto, Canada, 2000.
10. Ostrosky-Zeichner L, Paetznick VL, Mohr J, Rodriguez JR, Chen E, Sancak B, Rex JH. In Vitro Antifungal Activity of FK-463 against Candida spp, abstr. 197. In
Program and abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
11. Ostrosky-Zeichner L, Bazemore SA, Paetznick VL, Rodriguez JR, Chen E,
Wallace TL, Rex JH. Antifungal Activity of Isomeric Forms of Nystatin (NYS), abstr. 1956.In Program and abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
12. Ostrosky-Zeichner L, Paetznick VL, Sancak B, Rodriguez JR, Chen E, Rex JH. Correlation of minimum inhibitory concentrations (MIC) and disk diffusion diameters (DDID) for FK-463 in 403 bloodstream isolates of Candida spp., abstr J-572. In Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001.
13. Paphitou NI, Paetznick VL, Ostrosky-Zeichner L, Rodriguez JR, Chen E, Rex JH. In vitro activity of investigational triazoles against Trichosporon spp., abstr. J-814. In Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001.
14. Paphitou NI, Paetznick VL, Ostrosky-Zeichner L, Rodriguez JR, Chen E, Rex JH. In Vitro Activity of Investigational Triazoles against Fusarium: Effects of Inoculum size, and Time of Reading on Broth Microdilution Susceptibility Test Results, abstr. J-573. In Program and abstracts of the 41st Interscience Conference on
Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001.
15. Ostrosky-Zeichner L, Rex JH, Hammill RJ, Larsen RA, Horowitz H, Powderly WG, Pappas PG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, Lee J, for the NIAID-MSG Candidiasis Subproject. Three Year Survey of Regional and Temporal Trends in Fluconazole (FLU) Resistance (R) Among Bloodstream Candida spp. Isolates from the United States (US), abstr. 643. In Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, USA, 2001.
16. Rex JH, Ostrosky-Zeichner L, Pappas PG, Hamill RJ, Larsen RA, Horowitz H, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, Lee J, for the NIAID-MSG Candidiasis Subproject. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates from the United States (US), abstr. 642. In Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, USA, 2001.
17. Andrade R, Ostrosky-Zeichner L, Paetznick V, Rodriguez J, Chen E, Dudley M, Rex JH.Synergistic Antifungal Effect of Fluconazole (FLU) and CDR1/2 Efflux Pump Inhibitors: Insights into the Trailing Growth Phenomenon, abstr. M-223. In Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002.
18. Matar M, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, and Rex JH. Correlation between Etest (ET), Disk diffusion (DD) and Microdilution (MD) Methods for Antifungal Susceptibility Testing of Fluconazole (FLU) and Voriconazole (VOR), abstr. M-1495. In Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002.
19. Ostrosky-Zeichner L, Matar M, Paetznick VL, Rodriguez JR, Chen E, and Rex JH. In Vitro Synergy Testing of Anidulafungin (AFG) and Micafungin (MFG) in
Combination with Amphotericin B (AMB) Against Aspergillus spp. and Fusarium spp., abstr. M-1816 In Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002.
20. Odabasi Z, Mattiuzzi G, Ostrosky-Zeichner L, Estey E, Kantarjian H, Rex JH. Detection of (1->3)-b-D-Glucan (BG) in the Serum of Leukemia Patients (pts) with Invasive Fungal Infections (IFI), abstr. M-902. In Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002.
21. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Developing Criteria for Risk-Stratified Prophylaxis (PRX) of Invasive Candidiasis (IC) in the ICU, abstr. M-1239. In
Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 2002.
22. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, and Rex JR. Voriconazole (VOR) Salvage Treatment of Invasive Candidiasis (IC): Experience from Open-Label Compassionate Use Protocols. Abstr. 352. 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, USA, 2002.
23. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie E, Rex JR, Buell DN. Micafungin (MCFG), an Echinocandin Antifungal Agent for the Treatment of New and Refractory Candidemia. Abstr. 35. Focus on Fungal Infection 13, Maui, USA, 2003.
24. Grimes CZ, Peninger M, Ostrosky-Zeichner L, Clifton G, Nates JL, and Rex JH. Comparison of three definitions to determine ventriculostomy-related ventriculitis rates in neurological trauma patients. Abstr 43M. 30th Annual Meeting of the Association for Practitioners of Infection Control, San Antonio, Texas, USA, 2003.
25. Peninger M, Ostrosky-Zeichner L, Fisher V, Wright S, Grimes CZ, Wanger A, Rex JH. Infection control during a devastating flood event: Recovery and lessons
learned. Oral presentation (blue ribbon winner). 30th Annual Meeting of the
Association for Practitioners of Infection Control, San Antonio, Texas, USA, 2003.
26. Garbade D, Wright B, Valdivia A, Peninger M, Luther K, Cocanour C, Ostrosky-Zeichner L. A process measurement program decreased the rate of ventilator-associated pneumonias in a Surgical/Trauma Intensive Care Unit (STICU). Abstr. 117M. 30th Annual Meeting of the Association for Practitioners of Infection Control, San Antonio, Texas, USA, 2003.
27. Fisher V, Rex JH, Ackert-Burr C, Peninger M, Ostrosky-Zeichner L. Operating Room Staff Attitudes Toward Brushless vs. Traditional Surgical Hand Scrubbing. Abstr. 111M. 30th Annual Meeting of the Association for Practitioners of Infection Control, San Antonio, Texas, USA, 2003.
28. Ostrosky-Zeichner L. Prophylaxis in the ICU: New Approaches. Abstr. 394. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
29. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Rex JH, Ostrosky-Zeichner L. (1→3)-β-D-Glucan (BG) for the Diagnosis of Invasive Fungal Infections (IFI) in Leukemia Patients on Antifungal Prophylaxis. Abstr. M-1028. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003. 30. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR,
Ostrosky-Zeichner L. Differences in Beta-glucan (BG) levels in culture supernatants of a variety of fungi. Abstr. M-1021. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
31. Ostrosky-Zeichner L, Philip A, Odabasi Z, Paetznick VL, Rodriguez JR, chen E, Rex JH. Comparison of Colony Forming Unit (CFU) Counts and Quantitative PCR (qPCR) Conidial Equivalent (CE) Measurement in a Murine Model of Fusariosis. Abstr. M-362. 43rd Interscience Conference on Antimicrobial Agents and
Chemotherapy, Chicago, 2003.
32. Ostrosky-Zeichner L, Mohr J, Finkel KW, Rodriguez JR, Rex JH. Pharmacokinetics and safety evaluation of IV itraconazole/cyclodextrin (IV-ITR) in stable hemodialysis (HD) patients. Abstr. M-2056. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
33. Philip A, Odabasi Z, Rodriguez JR, Paetznick VL, Chen E, Ostrosky-Zeichner L, Rex JH. In Vitro Synergy Testing of Anidulafungin (ANID) with Itraconazole (ITR) and Voriconazole (VOR) against Aspergillus spp. and Fusarium spp. Abstr. M-988. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
34. Philip A, Odabasi Z, Mattiuzzi G, Paetznick VL, Rex JH, Ostrosky-Zeichner L. SysCan3 for the detection of anti-Candida antibodies for the diagnosis of invasive candididiasis (IC). Abstr. M-2060. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
35. Ostrosky-Zeichner L, Alexander B, Kett D, Vazquez J, Pappas P, Saeki F,
Ketchum PA, Wingard JR, Schiff RA, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1,3) beta-d-glucan (BG) assay(glucatell) as an aid to
diagnosis of invasive fungal infections (IFI) in humans. Late-breaker Abstr. M-1034a. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
36. Mohr JF, Lewis JH, Wanger A, Ostrosky-Zeichner L. Optimizing Pharmacodynamic (PD) Indices in Critically Ill Patients. Abstr. 194. 41st Annual Meeting of the
Infectious Diseases Society of America, San Diego, California, USA, 2003. 37. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Pilot
Survey of Anidulafungin (ANI) Against Selected Mould Isolates. 9th Congress of the European Confederation of Medical Mycology and 7th Trends in Invasive Fungal Infections. Abstr. O3.05. Amsterdam, The Netherlands, 2003.
38. Mohr JM, Ostrosky-Zeichner L, Wanger A, Ericsson CD. Antibiotic Use and Emergence of MRSA Over an 8 Year Period: An Analysis of 12 Different Time Periods. Abstr. 135. American College of Clinical Pharmacy Annual Meeting, 2003. 39. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, Kan V,
Kauffman CA, Kett D, Larsen R, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Wallace D, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis(IC) in the intensive care setting. Abstr 51. Focus on Fungal Infections 14, New Orleans, USA, 2004.
40. Fisher V, Peninger M, Tharp E, Waters D, Rex J, Ostrosky-Zeichner L. Four-Year Sustainability of a Post-Coronary Artery Bypass Graft (CABG) Surgical Site Infection (SSI) Prevention Program. Abstr. 322. 14th Annual meeting of the Society of
Healthcare Epidemiology of America, Philadelphia, USA, 2004.
41. Ostrosky-Zeichner L, Peninger M, Cocanour CS, Maguire L, Garbade D, Tidemann T, Domonoske BD, Li T, Luther KM. Assessment of the Economic Impact of a
Ventilator-Associated Pneumonia (VAP) Prevention Program in a Shock Trauma ICU (STICU) Using Unit-Specific Financial Estimates. Abstr. 145. 14th Annual meeting of the Society of Healthcare Epidemiology of America, Philadelphia, USA, 2004.
42. Peninger M, Philip A, Ostrosky-Zeichner L. A Probable SARS Case in Houston: Putting Hospital Plans to the Test. Abstr. 67. 14th Annual meeting of the Society of Healthcare Epidemiology of America, Philadelphia, USA, 2004.
43. Tidemann T, Peninger M, Fisher V, Wanger A, Ostrosky-Zeichner L. A Multi-unit, Poly-Clonal, Multi-Drug-Resistant (MDR) Acinetobacter baumannii Outbreak in a Tertiary Care Center. Abstr. 124. 14th Annual meeting of the Society of Healthcare Epidemiology of America, Philadelphia, USA, 2004.
44. Wright S, Peninger M, Taylor L, Putney A, Pearson P, Ostrosky-Zeichner L. Post-C-Section Endometritis Computer-Assisted Surveillance: Does it Work? Abstr.
#22357. 31st Annual Meeting of the Association for Practitioners of Infection Control, Phoenix, Arizona, USA, 2004.
45. Mohr J, Maddock J, Ericsson C, Wanger A, Peninger M, Ostrosky-Zeichner L. Antibiotic Utilization and Expenditures after the Discontinuation of an Antibiotic Stewardship Program (ASP). Abstr. O-1605/513. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004.
46. Ostrosky-Zeichner L, Rex JH, Paetznick VL, Rodriguez JR, Chen E, Pappas PG, Dismukes WE. Lack of Correlation of In Vitro Checkerboard-Based Antifungal Combination Results with Clinical Outcomes. Abstr. M-1679. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. 47. Espinel-ingroff AV, Pfaller M, Brown S, Ghannoum M. Manavathu E,
Ostrosky-Zeichner L, Rinaldi M, Schell W, Walsh T. Quality Control Guidelines for NCCLS Broth Microdilution Susceptibility Method (M38-A document) for Four Antifungal Agents. Abstr. M-1789/477. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004.
48. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between Microdilution (MD), E-test (ET) and Disk Diffusion (DD) Methods for
Antifungal Susceptibility Testing of Posaconazole. Abstr 24. Focus on Fungal Infections 15, Miami, USA, 2005.
49. Nolen T, Dimmick B, Kendrick A, Wallace D, Ostrosky-Zeichner L. Web
Application for Expedited Data Review. Society for Clinical Trials Annual Meeting, Portland, OR, May 2005.
50. Mohr JF, Paetznick V, Rodriguez J, Finkelman M, Cocanour CS, Rex JH, Ostrosky-Zeichner L. A Prospective Pilot Survey of B-glucan Seropositivity and Its
Relationship to Invasive Candidiasis in the Surgical ICU. Abstract #M-168. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, 2005.
51. Fisher V, Tidemann T, Promecene PA, Ostrosky-Zeichner L. Financial and morbidity impact of a program to decrease C-section-related infections (CSRI) in a tertiary care center. Abstract #K-1373. 45th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Washington DC, 2005.
52. Espinel-Ingroff AV, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller M, Rinaldi M, Schell W, Walsh T. Broth Microdilution Guidelines for Susceptibility Testing of Anidulafungin against Filamentous Fungi (Moulds). Abstract #M-1605.
45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, 2005.
53. Mohr JF, Wanger A, Ostrosky-Zeichner L, Ericsson CD. Increasing Piperacillin-Tazobactam Usage Does Not Reduce the Prevalence of Vancomycin Resistant Enterococci. Abstract #436. 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco CA, 2005.
54. Mohr JF, Wanger A, Ostrosky-Zeichner L, Ericsson CD. Risk factors for
vancomycin resistant enterococci in hospitalized adults compared to vancomycin susceptible enterococci. Abstract #480. 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco CA, 2005.
55. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L.
Contemporary Treatment and Outcomes of Zygomycosis in a Non-Oncological Tertiary Care Center. Abstract #273. 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco CA, 2005.
56. Sims CR, Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, Chen E. Comparison of Abelcet and Voriconazole Alone and in Combination in a Murine Model of
Fusariosis Using Survival and Organ Clearance by TaqMAn qPCR. Abstract P049. Focus on Fungal Infections 16, Las vegas, NV, USA, 2006.
57. Musgrove R, Fisher V, Gulley T, Ostrosky-Zeichner L. Beyond Bundles: Justification for a Central Venous Catheter (CVC) Care Team Program for the Prevention of Bloodstream Infections. Abstract 11. 33rd Annual Meeting of the Association for Practitioners of Infection Control. Tampa FL, 2006.
58. Jean W, Fisher V, Grubb L, Douglas G, Ostrosky-Zeichner L. Infection Control as the Real Bug Patrol: “Gnats” in the Burn Unit. Abstract 9-73. 33rd Annual Meeting of the Association for Practitioners of Infection Control. Tampa FL, 2006.
59. Davis B, Fisher V, Ostrosky-Zeichner L, Luther K, Peruzzi W. Translating Quality and Infection Control into Tangible Terms: A Tertiary Care Center’s Contribution to the Institute of Healthcare Improvement (IHI) 100K Lives Campaign. Abstract 13-129. 33rd Annual Meeting of the Association for Practitioners of Infection Control. Tampa FL, 2006.
60. Mohr J, Peyman P, Troxell E, Lodise T, Ostrosky-Zeichner L. (K-1421) Risk Factors Associated with Hyperglycemia in Patients Receiving Gatifloxacin (G) and Levofloxacin (L). Abstract #K-1421. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006.
61. Mohr J, Wanger A, Rogers D, Liu T, Earhart K, Ostrosky-Zeichner L. Phenotypic and Molecular Characteristics of Relapsing Candida Glabrata (CG) Bloodstream Infection During Caspofungin (CFG) Treatment. Abstract #M-1760. 46th
Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006.
62. Faiz SA, Neal BW, Rios E, Campos T, Parsley E, Patel B, Ostrosky-Zeichner L. Risk-based Fluconazole (FLU) Prophylaxis of Candida Bloodstream Infection (CBSI) in a Medical ICU. Abstract #K-274. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006.
63. Ostrosky-Zeichner L, Pappas P, Shoham S, Reboli A, Barron M, Sims C, Wood C, Sobel J. (M-883) Revalidation and Improvement of a Clinical Prediction Rule (CPR) for Clinical Trials on Prophylaxis of Invasive Candidiasis (IC) in the ICU. Abstract #M-883. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006.
64. Sims CR, Mohr J, Paetznick V, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of Clinical Outcomes with β-Glucan (BG) Levels in Patients with Invasive Candidiasis (IC). Abstract #M-1599. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006.
65. Chaturvedi V, Ramani R, Ghannoum M, Killian S, Holliday N, Knapp C, Ostrosky-Zeichner L, Messer S, Pfaller M, Iqbal N, Skaggs B, Perri MB, Vazquez J, Sein T, Walsh T. (M-1569) Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of Candida krusei. Abstract #M-1569. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, 2006. 66. Rios E. Ostrosky-Zeichner L. Incidence and Magnitude of Potential and Actual
Antifungal Drug Interactions in Candidemic Patients. Abstract #P0046. Focus on Fungal Infections 17, San Diego, CA, USA, 2007.
67. Brown S, Ostrosky-Zeichner L. Brown Water in the Building: Infection Control and Engineering Lessons Learned from a Water Supply Incident. Abstract 8-87. 34rd Annual Meeting of the Association for Practitioners of Infection Control. San Jose CA, 2007.
68. Jean W, Gaines B, Fisher V, Johantges D, Gonzalez E, Avery Y, Douglas G, Wanger A, Ostrosky-Zeichner L. A Complex Outbreak of Multi-Drug Resistant Acinetobacter (MDRA) in Multiple Adult ICUs at a Tertiary Care Center: The
Importance of Teamwork. Abstract 10-137. 34rd Annual Meeting of the Association for Practitioners of Infection Control. San Jose CA, 2007.
69. Mattiuzzi G, Kantarjian H, Odabasi Z, Alvarado G, Cassat J, Paetznick V, Rodriguez J, Chen E, Ostrosky-Zeichner L. Diagnostic Performance of Serum
Galactomannan (GM) and Beta Glucan (BG) in a Cohort of 395 Patients (pts) with Acute Leukemia on Antifungal Prophylaxis (AP). Abstract M-578. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
70. Mohr J, Ostrosky-Zeichner L, Ericsson CD, Wainwright D, Parks D, Hollenbeck T. Pharmacokinetic (PK) Evaluation of Single Dose Intravenous Daptomycin (D) in Patients with Thermal Burn Injury. Abstract A-793. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
71. Ostrosky-Zeichner L, Sobel J, Pappas P, Shoham S, Barron M, Reboli A, Kauffman C, Donowitz G, Clark N, Walsh T, Akins R, Mandviwala T, Shinde R, Bradley ME, Nolen T, Kendrick A, Wallace D. Pilot Study of Risk-Based
Caspofungin (CFG) Prophylaxis in the ICU: Lessons from a Multicenter, Randomized, Double Blind Trial and Insights into Diagnostic Performance of
Surrogate Markers. Abstract M-1158. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
72. Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, Chen E, Sheehan DJ. Activity of Anidulafungin (AFG) in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Serum Beta Glucan (BG) Levels. Abstract M-1840. 47th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
73. Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, Chen E, Kartsonis NA, Douglas C. Activity of Caspofungin (CFG) Alone and in Combination with Amphotericin B Lipid Complex (ABLC) in a Murine Model of Fusariosis. Abstract M-1841. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
74. Ostrosky-Zeichner L, Pfaller M, Diekma D, Andes D, Rinaldi M, Fothergill A,
Pappas P, Lortholary O, Mohr J, Kovanda L, Villmann M, Buell D. A Proposal for an Antifungal Susceptibility Testing (AST) Breakpoint for Micafungin (MFG) and
Candida: Integration of AST Surveys and Correlation with Clinical Outcomes. Abstract M-2020. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007.
75. Ostrosky-Zeichner L, Mattiuzzi G, Xiao L, Kantarjian H, Rodriguez J, Chen E, Paetznick V. Preliminary report of a possible association of voriconazole with false positive (1, 3)-b-D-glucan (BG): Important implications for diagnosis, therapeutic monitoring, and research. Abstract #27. Focus on Fungal Infections 18, San Antonio, TX, USA, 2008.
76. Hodges C, DeKay K, Metcalf A, Ostrosky-Zeichner L, Kreuzer S, Bell M, Woltman E, Morrison C, Wilson M, Schneider A, Ajouz L, McGlothlin M, Thomson K. Six Sigma and Infection Control: a Hybrid Program For the Prevention of Orthopedic Hip and Knee Infections. Abstract #5-43. 2008 APIC Annual Conference, Denver, CO, USA, 2008.
77. Fisher V, Johantges D, Gaines B, Jean W, Kamencik J, Katz J, Andrews W,
Ostrosky-Zeichner L. “Bundling” Best Care Practices to Improve Patient Outcomes in a Tertiary Care Center: Every Time for Every Patient. Abstract K-481. Combined 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting, Washington CD, 2008. 78. Cornely OA, Ostrosky-Zeichner L, Morris ML, Ullmann AJ, Wu C, Buell DN,
Kovanda L, Horn DL. Non-drug Factors Related to Survival and Treatment Success in Patients with Invasive Candidiasis or Candidemia: A Meta-Analysis of Two Large, Prospective, Micafungin Trials. Abstract K-1393. Combined 48th Interscience
Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting, Washington CD, 2008.
79. Ostrosky-Zeichner L, Aranha I, Eggiman P, Garbino J. Herbrecht R, Leon C, Lortholary O, Pappas P, Sobel J, Sorrell T, Muller E. Preliminary Results of a
Multicenter, International, Retrospective, Study to Validate a Clinical Prediction Rule (CPR) to Identify Critically-Ill Patients at Risk of Invasive Candidiasis (IC) for
TReatment with Empirical Antifungal Therapy (TREAT Study). Abstract M-1853. Combined 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting, Washington CD, 2008.
80. Chaturvedi V, Ramani R, Andes D, Brandt M, Diekema DJ, Pfaller MA, Ghannoum MH, Knapp C, Ostrosky-Zeichner L, Walsh TJ, Marchillo K, Iqbal N, Messer S, Welshenbaugh A, Bastulli C, Paetznick V, Rodriguez J, Sein T. Mutlilaboratory Testing of Antifungal Combinations. Abstract M-1538. Combined 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious
Diseases Society of America Annual Meeting, Washington CD, 2008. 81. Espinoza C, Fisher V, Jean W, Gaines B, Davis K, Wanger A, Schaeffer M,
Ostrosky-Zeichner L. A Pilot Study of Active Surveillance for MRSA by PCR on Admission to ICUs at a Tertiary Care Center. Abstract K-3367. Combined 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting, Washington CD, 2008. 82. Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, Kovanda
LL, Cornely OA. Non-Drug Factors Related to Survival in Patients with Invasive Candidiasis or Candidemia in Two Large, Phase 3, Micafungin Trials. 38th
Congress of the Society of Critical Care Medicine (SCCM), Nashville, TN, USA, January 31- February 4, 2009.
83. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of Candidemia and Invasive Candidiasis in the Intensive Care Unit: Post Hoc Analysis of a Randomized, Controlled Trial Comparing Micafungin and Liposomal Amphotericin B. 19th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Helsinki, Finland, May 16-19, 2009.
84. Ostrosky-Zeichner L, Inurria N, Rodriguez J, Chen E, Paetznick V. Comparative In Vitro Activity of Isavuconazole (ISA) against Medically Important Yeasts and Moulds. Abstract M-1707. 49th Interscience Conference on Antimicrobial Agents and
Chemotherapy , San Francisco, California, 2009.
85. Krishnan S, Kruzel M, Wanger A, Chen E, Rodriguez J, Paetznick V, Ostrosky-Zeichner L. Contemporary Epidemiology of Candidemia (CA) in a Tertiary Care Center: Insights into Molecular Epidemiology. Abstract M-1012. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy , San Francisco, California, 2009.
86. Hall AC, Gulbis BE, Krishnan S, Denktas AE, Ostrosky-Zeichner L. Incidence of Infection in Patients with Sudden Cardiac Death (SCD) Admitted to a Coronary Care Unit (CCU). Abstract K-285. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy , San Francisco, California, 2009.
87. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ for The CLSI Antifungal Testing Subcommittee. Wild Type Minimum Inhibitory Concentration (MIC) Distribution and Epidemiological Cutoff Values (ECVs) for Aspergillus fumigatus and Triazoles Using Clinical and Laboratory Standards Institute (CLSI) Method. Abstract M-1716. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy , San
Francisco, California, 2009.
88. Jean W, Blum N, Fisher V, Douglas G, Flanagan T, Ostrosky-Zeichner L. The “A team”: An environmental services intervention to control Multidrug-resistant
Acinetobacter. Abstract 598. 5th Decennial International Conference on Healthcare-Associated Infections. Atlanta, Georgia, USA, March 18-22, 2010.
89. Blum N, Jean W, Wanger A, Kuzel M, Fisher V, Ostrosky-Zeichner L. Validation of an Environmental Culturing Technique for Multi-Drug Resistant Acinetobacter
baumanni. Abstract 596. 5th Decennial International Conference on Helathcare-Associated Infections. Atlanta, Georgia, USA, March 18-22, 2010.
90. Chacon J, Bigbee J, Fisher V, Ostrosky-Zeichner L. Healthcare-Associated Infections (HAIs) in a Neurosurgical Intensive Care Unit (NSICU). Abstract 928. 5th Decennial International Conference on Healthcare-Associated Infections. Atlanta, Georgia, USA, March 18-22, 2010.
91. Krishnan S, Mattiuzzi G, Cortes J, Rodriguez J, Ostrosky-Zeichner L. M-417 - Kinetics of (1,3) Beta-D-Glucan (BG) in Patients with Hematologic Malignancies Receiving Voriconazole (VOR) Prophylaxis. Abstract M-417. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, 2010.
92. Meletiadis J, Andes D, Lockhart SR, Ghannoum MA, Knapp C, Ostrosky-Zeichner L, Pfaller MA, Walsh TJ. Multicenter Collaborative Study of the Interaction of
Antifungal Combinations against Candida spp. M-371. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, 2010.
93. Espinel-Ingroff AV, Canton E, Fothergill A, Rinaldi M, Ghannoum M, Isham N, Gibbs D, Wang A, Johnson E, Jones R, Messer S, Ostrosky-Zeichner L, Paetznick V, Schell W. Quality Control (QC) Limits for Antifungal Disk Diffusion Susceptibility Testing of Filamentous Fungi (Moulds) to Itraconazole, Posaconazole, Voriconazole & Amphotericin B. M-381. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, 2010.
94. Viola GM, Awan LL, Ostrosky-Zeichner L, Chan W, Darouiche RO. Infections of Cardiac Rhythm Management Devices: A Retrospective Multicenter Observational Study. Abstract 371. 48th Infectious Diseases Society of America Annual Meeting, Vancouver, BC, Canada, 2010.
95. Monney C, Upton D, Uribe S, Schneider K, Ostrosky-Zeichner L. Body mass index as a major risk factor for c-section-related surgical site infections (CSRSSI) and introduction of a prevention bundle. Abstract 495. 2011 Annual Meeting of the Society of Healthcare Epidemiology of America, Dallas, TX, April 1-4 2011. 96. Blum N, Wanger A, Kruzel M, Fisher V, Ostrosky-Zeichner L. Validation of
Hydrogen Peroxide Vapor Technology for Terminal Cleaning of Isolation Rooms. Abstract 108. 2011 Annual Meeting of the Society of Healthcare Epidemiology of America, Dallas, TX, April 1-4 2011.
97. Bigbee J, Blum N, Youens A, Ostrosky-Zeichner L. A Descriptive Analysis of CRUTIs Over a 6 Month Period in a Large Tertiary Care Facility. Abstract 598. 2011 Annual Meeting of the Society of Healthcare Epidemiology of America, Dallas, TX, April 1-4 2011.
98. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron M,
Schuster M, Judson MA, Revankar S, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman C, Larsen RA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG. MSG-01: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs
Placebo Followed by Pre-Emptive Therapy for Invasive Candidiasis (IC) in High-Risk Adults in the Critical Care Setting. Preliminary Results. Abstract LB-15. 2011 Annual Meeting of the Society of Healthcare Epidemiology of America, Dallas, TX, April 1-4 2011.
99. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-ß-D-Glucan (BG) as a Prognostic Marker of Treatment Response in Invasive Candidiasis. Abstract M-1139. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 2011.
100. Hogan P, Marček T, Vazquez JA, Paiva JA, Mootsikapun P, Ostrosky-Zeichner L. Geographic Distribution of Candida Species and Incidence of Multidrug Resistant (MDR) Isolates in Recent Clinical Studies of Anidulafungin for the Treatment of Candidemia/Invasive Candidiasis (C/IC). Abstract 03.1. 5th Trends in Medical Mycology, Valencia Spain, October 2-5, 2011.
101. Pokomo L, Fisher V, Morales M, Ostrosky-Zeichner L. Impact of active surveillance on the proportion of hospital-acquired Methicillin Resistant
Staphylococcus aureus (MRSA) infections in intensive care units. Abstract 53. 2012 Congress of the Society of Critical Care Medicine. Houston, Texas, April 4-8, 2012. 102. Corzo-Leon DE, Treviño-Rangel RJ, González G, Cornejo-Juarez P, Sifuentes-Osornio J, Ostrosky-Zeichner L. Candida Bloodstream Infections (CBSI): Species Distribution and Antifungal Susceptibility Patterns in the Mexican Medical Mycology Network. Abstract 1383. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, 2013.
103. Altshuler J, Guervil D, Ericsson CD, Wanger A, Ostrosky-Zeichner L. - Clinical Outcomes in Patients with Gram-Negative (GN) Infections Treated with Cefepime (CEF) Over Various Minimum Inhibitory Concentrations (MIC). Abstract K-1541.
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, 2013.
104. Ghannoum MA, Chaturvedi V, Espinel-Ingroff A, Fothergill A, Jones R, Ostrosky-Zeichner L, Rennie R, Walsh T. Intra- and Interlaboratory Study of Antifungal Susceptibility Testing of Isavuconazole against Aspergillus Strains. Abstract M-1351. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, 2013.
105. Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner L, Ericsson CD, Tam VH. Cefepime Free Minimum Concentration (fCmin) to Minimum Inhibitory Concentration (MIC) Ratio Predicts Clinical Failure in Patients with Gram-negative Bacterial Pneumonia. Abstract A-1328. 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.
106. Thompson GR, Rendon A, Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Zeiher B, Maher R, Lee M, Perfect J. Outcomes in Patients with Invasive Fungal Disease Caused by Dimorphic Fungi Treated with Isavuconazole: Experience from the VITAL Trial. Abstract M-1775. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.
107. Cornely OA, Ostrosky-Zeichner L, Rahav G, Maher R, Zeiher B, Lee M, Perfect J. Outcomes in Patients with Invasive Mold Disease Caused by Fusarium or
Scedosporium spp. Treated with Isavuconazole: Experience from the VITAL and SECURE Trials. Abstract M-1760. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.
Original Articles
1. Ostrosky L, Correa C., Faradji R, Garcia H, Flisser A. Taenia solium: Inhibition of spontaneous evagination of cysticerci by the host inflammatory capsule. Int J Parasitol 1991; 21: 603-4.
2. Soto-Hernadez JL, Ostrosky-Zeichner L, Tavera-Guittins GM, Gomez-Aviña A. Neurocysticercosis and HIV infection: Report of two cases and review. Surg Neurol 1996; 45:57-61.
3. Ostrosky-Zeichner L, Soto-Hernadez JL, Angeles-Morales V, Teixeira F, Nava-Ruiz C, Rios C, Solis F, Sotelo J. Effects of Pentoxifylline or Dexamethasone in Combination with Amphotericin B in Experimental Murine Cerebral Cryptococcosis: Evidence of Neuroexcitatory Pathogenic Mechanisms. Antimicrob Agents Chemother 1996; 40:1194-7.
4. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, Castañon-Olivares LR, Angeles-Morales V, Sotelo J. Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations. Mycopathologia 1996; 134:61-4.
5. Ostrosky-Zeichner L, Garcia-Mendoza E, Rios C, Sotelo J. Humoral and Cellular Immune Response within the Subarachnoid Space of Patients with Neurocysticercosis. Arch Med Res 1996; 27:513-7.
6. Corona T. Leon C, Ostrosky-Zeichner L. Severe Anaphylaxis with recombinant interferon beta. Neurology 1999; 52:425.
7. Ponce de León S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999; 353:1244.
8. Ostrosky-Zeichner L, Volkow P, Ponce de León S. Bronchoaspiration as a possible cause in a case of tetanus. A reminder on the importance of adulthood immunizations. Rev Inv Clin 1999; 51:131-3.
9. Tlatempa-Leyva L, Huertas-Jimenez M, Ostrosky-Zeichner L, et al. Costo beneficio de un equipo pre-empacado IV Start Pack, comparado con equipos tradicionales para instalación y curación de cateteres vasculares cortos. Enf Infec y Microbiol 1999; 19:59-63.
10. Ostrosky-Zeichner L, García N, Bornstein-Quevedo L, Romero-Lagarza AP. Ejercicio anatomo-clínico. Varón de 69 años con pancitopenia y sindrome de desgaste. Gac Med Mex 1999; 135:171-6.
11. Ostrosky-Zeichner L, Estañol B. Immunopathogenesis of Neurocysticercosis: Is damage mediated by the host immune response? Int J Parasitol 1999; 29:649-50. 12. Ostrosky-Zeichner L, Rangel-Frausto MS, Garcia-Romero E, Vazquez A, Ibarra MJ, Ponce de Leon-Rosales S. Tuberculosis in health personnel: importance of surveillance and control programs. Salud Publica Mex 2000; 42:48-52.
13. Ostrosky-Zeichner L, Baez-Martinez R, Rangel-Frausto MS, Ponce de Leon S. Epidemiology of Nosocomial Outbreaks: 14-Year Experience at a Tertiary-Care Center.Infect Control Hosp Epidemiol 2000;21:527-9.
14. Ostrosky-Zeichner L, Bazemore S, Paetznick VL, Rodriguez JR, Chen E, Wallace T, Cossum P, Rex JH. Differential Antifungal Activity of Isomeric Forms of Nystatin. Antimicrob Agents Chemother 2001; 45:2781-6
15. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In Vitro Antifungal Susceptibilities of Trichosporon spp. Antimicrob Agents Chemother 2002; 46:1144-6.
16. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick, V, Gordon D, Wallace T, Rex JH. In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates. J Clin Microbiol 2002; 40:1406-12.
17. Ripeau JS, Aumont F, Belhumeur P, Ostrosky-Zeichner L, Rex JH, De Repentigny L. Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro. Antimicrob Agents Chemother 2002;46:3096-100.
18. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In Vitro Activities of Investigational Triazoles against Fusarium Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results. Antimicrob Agents Chemother 2002; 46:3298–300.
19. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, Disk diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole. Antimicrob Agents
Chemother 2003; 47:1647-51.
20. Naninni E, Paphitou NI, Ostrosky-Zeichner L. Peritonitis Due to Aspergillus and Zygomycetes in patients Undergoing Peritoneal Dialysis: Report of 2 Cases and Review of Literature. Diagnost Microbiol Infect Dis 2003; 46:49-54.
21. Ostrosky-Zeichner L, Marr KA, Rex, JH, Cohen SH. Reviews of Anti-infectives: Amphotericin B: Time for a New “Gold Standard”. Clin Inf Dis 2003; 37:415-25. 22. Odabasi Z, Paetznick V, Goldstein BP, Rex JH, Ostrosky-Zeichner L. Disk
Diffusion-Based Methodologies for Determining Susceptibility of C. parapsilosis to Anidulafungin. Antimicrob Agents Chemother 2003; 47:3018-20.
23. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group Candidiasis Subproject. Comparative Antifungal Susceptibility Survey of 2,000 Bloodstream Isolates of Candida spp. from the United States. Antimicrob Agents Chemother 2003; 47:3149-54.
24. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, and Rex JR. Voriconazole Salvage Treatment of Invasive Candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651-5.
25. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In Vitro Antifungal Activity of Anidulafungin Against Selected Clinically Important Mould Isolates. Antimicrob Agents Chemother 2004; 48:1912-5.
26. Odabasi Z,Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cut-off Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clinical Infect Dis 2004; 39:199-205.
27. Odds FC, Motyl M, Andrade R, Bille J, Canton E, Cuenca-Estrella M, Davidson A, Durussel C, Ellis D, Foraker E, Fothergill AW, Ghannoum MA, Giacobbe RA, Gobernado M, Handke R, Laverdiere M, Lee-Yang W, Merz WG, Ostrosky-Zeichner L, Peman J, Perea S, Perfect JR, Pfaller MA, Proia L, Rex JH, Rinaldi MG, Rodriguez-Tudela JL, Schell WA, Shields C, Sutton DA, Verweij PE, Warnock DW. Interlaboratory Comparison of Results of Susceptibility Testing with
Caspofungin against Candida and Aspergillus Species. J Clin Microbiol 2004; 42:3475-82.
28. Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. Antimicrob Agents Chemother 2004; 48:3151-3.
29. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995–2002. Int J Antimicrob Agents 2004; 24:346-51.
30. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40 Suppl 6:S409-13.
31. Mohr JF, Hall AC, Ostrosky-Zeichner L, Ericsson CD. Amphotericin B Overdose: A Fatal Case of Lipid and Non-Lipid Formulation Mix-Up. Pharmacotherapy 2005;25:426–8.
32. Cocanour CS, Ostrosky-Zeichner L, Peninger M, Garbade D, Tidemann T, Domonoske BD, Li T, Allen SJ, Luther KM. Cost of a Ventilator-Associated
Pneumonia in a Shock Trauma Intensive Care Unit. Surg Infect (Larchmt) 2005; 6:65-72.
33. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at
increased risk for candidal infections in the surgical intensive care unit: An approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43:235-43.
34. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49:3572-4.
35. Philip A, Odabasi Z, Matiuzzi G, Paetznick VL, Tan S, Warmington J, Rex JH, Ostrosky-Zeichner L. Syscan3 for the Detection of anti-Candida antibodies for the diagnosis of Invasive Candidiasis. J Clin Microbiol 2005; 43:4834-5.
36. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter Clinical Evaluation of the (1→ 3) β-D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. Clin Infect Dis 2005; 41:654-9.
37. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller M, Rinaldi M, Schell W, Walsh T. Quality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for
Amphotericin B, Itraconazole, Posaconazole, and Voriconazole. J Clin Microbiol 2005;43:5243-6.
38. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-61.
39. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. Open-Label, Randomized Comparison of Itraconazole versus
Caspofungin for Prophylaxis in Patients with Hematologic Malignancies. Antimicrob Agents Chemother 2006; 50:143-7.
40. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR,
Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006;44:267-72.
41. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between Microdilution, E-test, and Disk Diffusion Methods for Antifungal
Susceptibility Testing of Posaconazole against Candida spp. J Clin Microbiol 2006;44:2105-8.
42. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of
zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007;38:90-3. 43. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V,
Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-6.
44. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet
2007;369:1519-27.
45. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller MA, Rinaldi MG, Schell W, Walsh TJ. Quality Control and Reference
Guidelines for CLSI Broth Microdilution Method (M38-A Document) for Susceptibility Testing of Anidulafungin against Molds. J Clin Microbiol 2007; 45:2180-82.
46. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clin Infect Dis 2007; 45:883-93.
47. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. Effects of Serum on In Vitro Susceptibility Testing of Echinocandins. Antimicrob Agents Chemother 2007; 51: 4214–16.
48. Kohli V, Smithee L, Ishihara K, Ostrosky-Zeichner L, Van Buren C, Lappin J, Harrington T, Kuehnert M, Piercefield E. Transplantation-Transmitted Tuberculosis — Oklahoma and Texas, 2007. MMWR 2008; 57:333-6.
49. Mohr JF, Peymann PJ, Troxell E, Lodise TP, Ostrosky-Zeichner L. Risk Factors for Hyperglycemia in Hospitalized Adults Receiving Gatifloxacin: A Retrospective, Nested Case-Controlled Analysis. Clinical Therapeutics 2008; 30:152-7. 50. Chaturvedi V, Ramani R, Ghannoum MA, Killian SB, Holliday N, Knapp C,
Ostrosky-Zeichner L, Messer SA, Pfaller MA, Iqbal NJ, Arthington-Skaggs BA, Vazquez JA, Sein T, Rex JH, Walsh TJ. Multilaboratory testing of antifungal
combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother 2008; 52:1500-2.
51. Mohr JF, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008; 52:1891-3.
52. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC
breakpoints. J Clin Microbiol. 2008; 46: 2620-9.
53. Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method. Antimicrob Agents Chemother 2008; 52:4175-7.
54. Nolen TL, Dimmick BF, Ostrosky-Zeichner L, Kendrick AS, Sable C, Ngai A, Wallace D. A web-based endpoint adjudication system for interim analyses in clinical trials. Clinical Trials 2009; 6:60-6.
55. Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, Chen E, Sheehan DJ. Activity of anidulafungin in a murine model of Candida krusei infection: Evaluation of mortality and disease burden by quantitative tissue cultures and serum (1,3) β-D-glucan levels. Antimicrob Agents Chemother 2009; 53:1639-41.
56. Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, Ostrosky-Zeichner L. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009; 28:689-92.
57. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee. Wild-type MIC distribution and
epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009;47:3142-6.
58. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13(5):R159. Epub 2009 Oct 5.
59. Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, Kovanda LL, Cornely OA. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis. 2010; 29:223-9.
60. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Rex JH, Leitz GJ, Ostrosky-Zeichner L. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Mycoses 2010; 53:438-422.
61. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, Wood C, Sobel JD. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011;54:46-51.
62. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L. A Prospective Survey of (1->3)-β-D-glucan and its Relationship to Invasive Candidiasis in the Surgical ICU Setting. J Clin Microbiol. 2011; 49:58-61. 63. Espinoza C, Fisher V, Jean W, Gaines B, Davis K, Wanger A, Brown E, Slomka J,
Ostrosky-Zeichner L. Prevalence and Risk Factors of Methicillin-Resistant Staphylococcus aureus Colonization among Critically Ill Hospitalized Patients in a Tertiary Care Center in Houston, Texas: An Active Surveillance Pilot Project. Infect Control Hosp Epidemiol. 2011;32:93-5.
64. Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, Knapp C, Lockhart SR, Ostrosky-Zeichner L, Walsh TJ, Marchillo K, Messer S,
Welshenbaugh AR, Bastulli C, Iqbal N, Paetznick VL, Rodriguez J, Sein T. Multi-laboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother. 2011; 55:1543-8.
65. Espinel-Ingroff A, Canton E, Fothergill A, Ghannoum M, Johnson L, Jones RN, Ostrosky-Zeichner L, Schell W, Gibbs DL, Wang A, Turnidge J. Quality Control Guidelines for Amphotericin B, Itraconazole, Posaconazole and Voriconazole Disk
Diffusion Susceptibility Tests on Non-supplemented Mueller-Hinton Agar (CLSI M51-A document) of Nondermatophyte Filamentous Fungi. J Clin Microbiol. 2011;49(7):2568-71.
66. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70(3):330-43.
67. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J. Cryptococcus neoformans-Cryptococcus gattii Species Complex: An International Study of Wild-Type Susceptibility Endpoint Distributions and
Epidemiological Cutoff Values for Amphotericin B and Flucytosine. Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13.
68. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MS, Ostrosky-Zeichner L, Pappas P, Pelaez T, Peman J, Rex J, Szeszs MW. Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution. J Clin Microbiol. 2012 Jun;50(6):2040-6.
69. Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of Clinical Outcomes with β-glucan Levels in Patients with Invasive Candidiasis. J Clin Microbiol. 2012 Jun;50(6):2104-6.
70. Viola GM, Awan LL, Ostrosky-Zeichner L, Chan W, Darouiche RO. Infections of cardiac implantable electronic devices: a retrospective multicenter observational study. Medicine (Baltimore). 2012;91:123-30.
71. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis. Clin Infect Dis. 2012;55(4):521-6.
72. Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem
MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. Cryptococcus neoformans-Cryptococcus gattii Species Complex: An International Study of Wild-Type Susceptibility Endpoint Distributions and
Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole and Voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898-906.
73. Ramireddy S, Wanger A, Ostrosky L. An instructive case of CNS histoplasmosis in an immunocompetent host. Med Mycol Case Reports 2012; 1:69-71.
74. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?
Antimicrob Agents Chemother. 2013;57(12):5836-42.
75. Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J. Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method. Antimicrob Agents Chemother. 2014;58(2):916-22.
76. Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J,
Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. A multi-laboratory study of epidemiological cutoff values for
azole-resistance detection of eight Candida spp. to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2014; 58(4):2006-12.
77. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA,
Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG. MSG-01: A randomized, double-blind, placebo controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014; 58(9):1219-1226.
78. Corzo-Leon DE, Alvarado-Matute T, Colombo AL, Cornejo-Juarez P, Cortes J, Echevarria JI, Guzman-Blanco M, Macias AE, Nucci M, Ostrosky-Zeichner L, Ponce-de-Leon A, Queiroz-Telles F, Santolaya ME, Thompson-Moya L, Tiraboschi IN, Zurita J, Sifuentes-Osornio J. Surveillance of Candida spp Bloodstream
